GLP1R and melanoma: Specifically, dual treatment with metformin and GLP‐1 RAs reduced the risk of hepatocellular (0.38 [0.30, 0.48]), colorectal (0.54 [0.44, 0.66]), pancreatic (0.69 [0.53, 0.91]), oesophageal (HR 0.37 [95% CI 0.22, 0.63]), stomach (0.56 [0.35, 0.90]), uterine (0.57 [0.44, 0.74]), breast (0.84 [0.73, 0.97]), kidney (0.49 [0.40, 0.59]), brain (0.50 [0.32, 0.7]), multiple myeloma (0.51 [0.37, 0.71]), head and neck (0.54 [0.37, 0.79]) cancers, and melanoma (0.59 [95% CI 0.41, 0.85]).